Apple loses bid to overturn $634 million Masimo patent verdict, new trial also denied

A federal judge has denied Apple's motions to overturn a $634 million patent infringement verdict and to secure a new trial in its long-running legal battle with Masimo. The verdict, which was reached in a trial that began in early 2020, concerns Apple's use of Masimo's blood oxygen sensor technology in certain Apple Watch models. The judge's decision makes the payment to Masimo final, with the funds going to Masimo's new owner, Danaher, following a recent acquisition. The trial did not result in a permanent ban on Apple Watch sales or the use of the blood oxygen sensor, but the financial penalty stands. Apple had argued for the verdict to be set aside, but the court rejected those arguments. This ruling is a significant setback for Apple in its ongoing patent disputes with Masimo, which have also involved import bans and other legal actions.

Global Impact

Economically, the ruling reinforces the financial consequences of patent infringement in the tech industry, with Apple facing a $634 million payout. Politically and legally, it underscores the importance of patent protection in the medical technology sector, potentially influencing future litigation strategies.